Company Analysis
Sign in

Artelo Biosciences, Inc. (ARTL)

Nasdaq: ARTL · Pharmaceutical Preparations · Solana Beach, CA · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.6
◀ Past 4.6● Present 4.3▶ Future 4.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$12.9M-31.1%
Earnings per share$-12.52+31.6%
Operating cash flow-$8.5M-2.0%
Cash$600,000-91.3%
Debtn/a
Shareholders’ equity-$1.3M-144.5%
Shares, diluted1,029,000+91.6%
Return on equityn/a
The recordfrom its filings
Filings in 202677
Newest filingNov 12 · 10-Q
Annual reportFeb 24, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted2
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$11.3MCash from operations -$11.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 9, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 27, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Jul 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Jul 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ARTL · research, not advice